From Riabini To Yuflama: These Are The Top Biosimilars Of 2021

A biosimilar is also called a subsequent entry biologic or a follow-on biologic. They are identical copies of the original medicine that was developed by a different company. Biosimilars are the officially approved versions of the original drugs and can be manufactured upon the expiration of the original drug.

The year 2021 brought in several biosimilar drugs that were both approved and launched. These include some expected entrants in the Humira market as well as the approval of the first insulin biosimilar. The following list gives an overview of some of the top biosimilar launches and approvals that took place in 2021.

Riabni

  • Developed by: Amgen Inc.
  • Biosimilar to: Rituxan (rituximab).
  • Treatment for: Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Non-Lymphoma Hodgkin’s (NHL), and Chronic Lymphocytic Leukemia (CLL).

Hanbeitai

  • Developed by: Henlius.
  • Biosimilar to: Bevacizumab.
  • Treatment for: Metastatic colorectal cancer (mCRC) and recurring, locally advanced, unresectable, or metastatic non-squamous non-small cell lung cancer.

Cyltezo

  • Developed by: Boehringer Ingelheim.
  • Biosimilar to: Humira (adalimumab).
  • Treatment for: Rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, Crohn’s disease, ankylosing spondylitis, plaque psoriasis, and ulcerative colitis.

SEMGLEE and Insulin Glargine Injection

  • Developed by: Biocon Biologics and Viatris Inc.
  • Biosimilar to: Lantus (insulin glargine).
  • Treatment for: Managing high blood sugar in pediatric (type 1 diabetes) and adult (type 2 diabetes) patients.

Onbevzi

  • Developed by: Boryung Pharmaceutical.
  • Biosimilar to: Avastin (bevacizumab).
  • Treatment for: Cervical cancer, primary peritoneal or fallopian tube cancer, glioblastoma, epithelial ovarian cancer, non-small cell lung cancer, advanced or metastatic renal cell carcinoma, metastatic colorectal cancer, and metastatic breast cancer.

Byooviz

  • Developed by: Samsung Bioepis and commercialized by Biogen.
  • Biosimilar to: Lucentis (ranibizumab).
  • Treatment for: Choroidal neovascularization, diabetic macular edema, macular edema secondary to retinal vein occlusion, neovascular (wet) age-related macular degeneration, and proliferative diabetic retinopathy.

Kixelle

  • Developed by: Biocon and Viatris.
  • Biosimilar to: Insulin Aspart (Novo Nordisk).
  • Treatment for: Type 2 diabetes in children aged one year and older, adolescents, and adults.

Yuflama

  • Developed by: Celltrion.
  • Biosimilar to: Adalimumab.
  • Treatment for: Ulcerative colitis, ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, rheumatoid, and juvenile idiopathic.

Source: Navigating the Biosimilar drug development — Key approval and launches, By Delveinsight.

--

--

--

Love podcasts or audiobooks? Learn on the go with our new app.

Recommended from Medium

Lеаrn Hоw tо Idеntіfу thе Sіgnѕ аnd Sуmрtоmѕ of Prоѕtаtе Cаnсеr

Nordicnaturals

Strategic Fit for the Next Healthcare

Wisdom of the Ages: Ten Essays from 2019 that Every Health Innovator Should Read

Discovery of Viral Peptides Paves the Way for Cheaper, More Accurate COVID Diagnostics

What Is the Noom Diet?

People-powered research: partnering with pharma to improve research

The Mysterious, Remarkable Memories of ‘Superagers’

Emergency Dentist in Gwernaffield / Y Waun #Urgent #Dental #Treatment #Gwernaffield #/ #Y #Waun…

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Davekevic

Davekevic

More from Medium

Steven Adams for MVP: How the Memphis Grizzlies Built a Top-10 Offense

Into The Furnace: Chapter 1

Twenty Twenty-One

Tempo of the Hour